Moderna Seeks FDA Emergency Approval For COVID-19 Vaccine

Image by fernando zhiminaicela from Pixabay

On Monday pharmaceutical giant Moderna is applying for emergency approval to the FDA for authorization of its coronavirus vaccine for emergency use. New data on Monday showed that it was 100 percent effective at preventing serious disease from the coronavirus.

Stephane Bancel, Chief Executive of Moderna said that he considered these statistics about prevention of severe disease to be the most important data from the recent study.

“This is why I think this vaccine is going to be a game-changer,” he said. The vaccine will reduce hospitalizations and deaths, he added, “and I hope get this country back to its pre-pandemic state.”

In November 2020, in the US, four million new cases were detected and there have been 25,500 deaths. The numbers may worsen in the following weeks due to holiday travel and gatherings for Thanksgiving.

According to Mr. Bancel, FDA scientists will examine the information and the application is likely to undergo a final review on December 17 by an expert advisers’ panel. Officials at Operation Warp Speed, the government’s program to accelerate vaccine development, say that vaccinations can start within 24 hours after FDA authorization.

Mr. Bancel said that the company was “on track” and would produce 20 million doses by the end of December, which would be sufficient for 10 million people, as each person needs two doses, administered a month apart. They are planning to produce 500 million to a billion doses by 2021.

Source The New York Times


Follow us on Google news for more updates and News










PLEASE READ THE IMPORTANT DISCLOSURES BELOW.

This content is being provided to you for informational purposes only. The content has been prepared by third parties not affiliated with CWEB Inc, a business. This content and any information contained therein, does not constitute a recommendation by CWEB to buy, sell or hold any security, financial product or instrument referenced in the content. This information neither is, nor should be construed as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. CWEB Inc. does not offer or provide any opinion regarding the nature, potential, value, suitability or profitability of any particular investment or investment strategy, and you shall be fully responsible for any investment decisions you make, and such decisions will be based solely on your evaluation of your financial circumstances, investment objectives, risk tolerance, and liquidity needs.

Unless stated otherwise, the web content provided by the CWEB family of companies is for educational purposes only. The information and tools provided neither are, nor should be construed, as an offer, or a solicitation of an offer, to buy or sell securities by CWEB Inc. or its affiliates. Unless stated otherwise, no information presented constitutes a recommendation by CWEB Inc. or its affiliates to buy, sell or hold any security, financial product or instrument discussed therein or to engage in any specific investment strategy.

Full Disclaimer

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.